r***u
发帖数: 1272 | 1 一、 国家及校级奖项、称号
国家奖学金 National Scholarship
国家励志奖学金 National Encouragement scholarship
三好学生标兵 Pacemaker to Merit Student
三好学生 Merit Student
学习优秀生 Model Student of Academic Records
突出才能奖 Model Student of Outstanding Capacity
先进个人 Advanced Individual/Outstanding Student
优秀工作者 Excellent staff
优秀学生干部 Excellent Student Cadre
优秀共青团员 Excellent League Member
优秀毕业生 Outstanding Graduates
优秀志愿者 Outstanding Volunteer
先进班集体 Advanced Class... 阅读全帖 |
|
c**i
发帖数: 6973 | 2 Peter Landers, New Breast Cancer Drug Found Deep in the Sea. Wall Street
Journal, Jan. 4, 2010.
http://online.wsj.com/article/SB1000142405274870411150457605977
("A study found it [Halaven] extended the life of patients with advanced
breast cancer by about two-and-1/2 months, to 13 months")
My comment:
(a) Eisai Co., Ltd. エーザイ株式会社
(a public company; headquarters Tokyo; established in 1941 by Toyoji NAITO
内藤 豊次 as Nohon Eisai Co., Ltd. 日本衛材（衛生材料の略。具体的には絆創膏
や包帯の事))
ja.wikipedia.org
(b) eribulin
htt... 阅读全帖 |
|
|
t*******h
发帖数: 409 | 4 In the second quarter of 2013, Arena recognized $1.3 million in net product
sales, which is 31.5% of Eisai's net product sales of BELVIQ.
In the third quarter of 2013, Arena recognized 31.5% of Eisai's net product
sales (which were $5.4 million), or $1.7 million,
sales 5.4M/Q 也太少了， but ~30% increase by Q is impressive
看下一个Q怎么样吧 |
|
t*******h
发帖数: 409 | 5 In the second quarter of 2013, Arena recognized $1.3 million in net product
sales, which is 31.5% of Eisai's net product sales of BELVIQ.
In the third quarter of 2013, Arena recognized 31.5% of Eisai's net product
sales (which were $5.4 million), or $1.7 million,
sales 5.4M/Q 也太少了， but ~30% increase by Q is impressive
看下一个Q怎么样吧 |
|
c**i
发帖数: 6973 | 6 Peter Landers, New Breast Cancer Drug Found Deep in the Sea. Wall Street
Journal, Jan. 4, 2010.
http://online.wsj.com/article/SB1000142405274870411150457605977
("A study found it [Halaven] extended the life of patients with advanced
breast cancer by about two-and-1/2 months, to 13 months")
My comment:
(a) Eisai Co., Ltd. エーザイ株式会社
(a public company; headquarters Tokyo; established in 1941 by Toyoji NAITO
内藤 豊次 as Nohon Eisai Co., Ltd. 日本衛材（衛生材料の略。具体的には絆創膏
や包帯の事))
ja.wikipedia.org
(b) eribulin
htt... 阅读全帖 |
|
c**i
发帖数: 6973 | 7 Peter Landers, New Breast Cancer Drug Found Deep in the Sea. Wall Street
Journal, Jan. 4, 2010.
http://online.wsj.com/article/SB1000142405274870411150457605977
("A study found it [Halaven] extended the life of patients with advanced
breast cancer by about two-and-1/2 months, to 13 months")
My comment:
(a) Eisai Co., Ltd. エーザイ株式会社
(a public company; headquarters Tokyo; established in 1941 by Toyoji NAITO
内藤 豊次 as Nohon Eisai Co., Ltd. 日本衛材（衛生材料の略。具体的には絆創膏
や包帯の事))
ja.wikipedia.org
(b) eribulin
htt... 阅读全帖 |
|
f**********g
发帖数: 2252 | 8 Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
Wednesday 10/06/2010 8:00 AM ET - Pr Newswire
Related Companies
Symbol Last %Chg
ARNA 1.84 4.51%
As of 10:13 AM ET 10/12/10
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today
upcoming lorcaserin presentations at Obesity 2010, the 28th Annual
Scientific Meeting of The Obesity Society, in San Diego, California.
Lorcaserin, which Arena discovered and developed, is intended for weight
management, includ... 阅读全帖 |
|
|
v**********m
发帖数: 5516 | 10 Cash/share (Dec 30, 2010)
$1.13/share ($150,669,000/133,680,000)
-----------------------------------------------------------
刚增发过，到明年没问题。
Arena Pharmaceuticals Announces $35.5 Million Financing
- Arena to Use Approximately $17.7 Million of Proceeds to Prepay Outstanding
Debt -
SAN DIEGO, March 29, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (
Nasdaq: ARNA) announced today that it has agreed to sell 12,150,000 shares
of its common stock, at a price of $1.46 per share, and 12,150 shares of it... 阅读全帖 |
|
v**********m
发帖数: 5516 | 11 FDA Accepts Resubmission Of Arena Pharmaceuticals And Eisai Inc's Lorcaserin
New Drug Application
8:01am EST
Arena Pharmaceuticals and Eisai Inc. announced that the US Food and Drug
Administration (FDA) has accepted for filing and review Arena's resubmission
of the New Drug Application (NDA) for lorcaserin. The FDA considers the
resubmission a complete, class 2 response, and assigned a new Prescription
Drug User Fee Act (PDUFA) target date of June 27, 2012. Lorcaserin is
intended for weight mana... 阅读全帖 |
|
|
W********g
发帖数: 610 | 13 税收五年一直处于增长状态...cash充足，我觉得风险相对于BPAX小一些
James S. J. Manuso
Thank you, Tim. Good afternoon, and thank you for joining us for Astex
Pharmaceuticals 2012 First Quarter Conference Call. During the quarter, we
made considerable operational progress on many fronts in discovery, research
and in the clinical and regulatory development of our drugs. Our balance
sheet remains sound and our financial performance was excellent. We ended
the quarter with $126 million in cash and marketable securities and we
po... 阅读全帖 |
|
|
h*******g
发帖数: 205 | 15 看到一个5/14的帖子，没事看看吧，反正都是讲ARNA和VVUS的，个人观点，热火朝天的
，呵呵。
http://www.investorvillage.com/smbd.asp?mb=633&pt=msg&mn=%20213
Msg 21332 of 30450 at 5/14/2012 5:42:40 AM by
tarado96
I agree with this poster concerning ARNA near target prices: $20, and $35 (
with EMA approval)
Lorcaserin published in NEJM:worlds' most prestigious clinical journal
By far the most prestigious clinical publication in the world is NEJM (
impact factor 53.5) vs the distant second Lancet (impact factor 33.6). One
has to a... 阅读全帖 |
|
t********t
发帖数: 5415 | 16 OREX还得等等吧，至少1年半才能见到药片。VVUS倒是能最先上市不过也是副作用最大
的。从安全角度看来还是ARNA好一些。VVUS会提高心率，心血管不好的人可能会出问题
，而肥胖者心血管不好的概率...倒是FDA release里这一段很有意思：VVUS低剂量吃12
周之后减不掉3%的可以上高剂量，再12周之后减不掉5%的才停药...这个不需要detox么？
VVUS会有比ARNA多得多的限制（一个REMS，10个post study，自己出钱 vs ARNA没有
REMS，5-6个post study，eisai给出钱），少不少的适用人群，等到sales数据出来再
看吧 |
|
b******9
发帖数: 2706 | 17 不是吧？ 老兄你没FOLLOW近期的消息？ EISAI已经向DEA申请WAIVER ON RESPOND
PERIOD。 然后说它家的SALES，MARKETING部门都已经准备新药LAUNCH了。 ARNA现在找
的是欧洲和中国的合作伙伴。
BELVIQ最早1／18可以上市。 |
|
s*******d
发帖数: 3786 | 18 要爆了
Arena Pharmaceuticals Reports That Eisai Will Double BELVIQ® (
lorcaserin HCl) CIV Sales Force by December |
|
s*******d
发帖数: 3786 | 19 要爆了
Arena Pharmaceuticals Reports That Eisai Will Double BELVIQ® (
lorcaserin HCl) CIV Sales Force by December |
|
p**********e
发帖数: 703 | 20 Concerning obesity drug, I trust Spencer Osborne who always give fair
analysis
More info. here:
http://seekingalpha.com/article/1871711-orexigen-announces-100-
esp. the last paragraph
In my opinion, Orexigen is still a "wait and see" play. For the sector, I
see January and February of 2014 as a key time period. Arena and its partner
Eisai should be ramping up a more aggressive ad campaign that should bring
consumer awareness, and insurance companies should be adjusting formularies
on obesity tre... 阅读全帖 |
|
p**********e
发帖数: 703 | 21 If 收购, it should be Eisai, isn't it??? |
|
p**********e
发帖数: 703 | 22 Eisai has been doing marketing in so many countries even before it was
approved...I got lost... |
|
t*******h
发帖数: 409 | 23 拜托
去arna的网上看一看
right 都卖60M给Eisai了
怎么可能改嫁？ |
|
p**********e
发帖数: 703 | 24 To me, it is less likely by GSK if ARNA is ready to sell....but so far,
Eisai had put a lot of money in it and not much back yet, so IF it is really
GSK, they would have to pay at least 20 or more a share....even $10 is
ridiculous.... |
|
p**********e
发帖数: 703 | 25 To me, it is less likely by GSK if ARNA is ready to sell....but so far,
Eisai had put a lot of money in it and not much back yet, so IF it is really
GSK, they would have to pay at least 20 or more a share....even $10 is
ridiculous.... |
|
|
|
|
|
|
b******e
发帖数: 3348 | 31 英语日语？
正确按照日语的发音应该是“挨宰”，汉字是“卫材”。 |
|
j****x
发帖数: 1704 | 32 http://blog.sina.com.cn/s/blog_77f807030101ig90.html
肿瘤免疫疗法是当前肿瘤治疗领域最具前景研究方向之一，各大药企纷纷寻求与其他公
司合作研发肿瘤免疫相关治疗方法。初步的临床试验结果表明其治疗有效率非常高，
Science杂志也将肿瘤免疫疗法评为2013年十大科学突破第一位。
本文首先介绍肿瘤免疫疗法在肿瘤治疗中的地位，然后是作用机制和具体分类，已经上
市或在研药物、市场预测，最后列举各公司之间的收购合作及国内部分参与相关研发的
公司。
1肿瘤治疗发展历程
1.1传统疗法
包括手术切除、化疗、放射线治疗。其具有局限性：手术切除的方式常因为癌细胞入侵
蔓延到邻近组织或远端转移而效果有限；化疗受限于对体内其他正常组织的毒性；放疗
辐射也同样会对正常组织造成伤害。传统疗法都是对身体有极大负担，并且在发生恶性
转移后，无论是何种方式都是很难彻底治愈。
1.2靶向疗法
20世纪末出现的靶向疗法是在细胞分子水平上，针对已经明确的致癌位点来设计相应的
治疗药物，药物进入体内会特异地选择致癌位点来相结合发生作用，使肿瘤细胞特异性
死亡，而不会伤及肿瘤... 阅读全帖 |
|
c******n
发帖数: 16403 | 33 Merck： 0
Pfizer： 0？
BMS： 3
Amgen： 0 （will lay off 500 soon）
Lilly: 3
genentech: 2-3
Novartis: 5-6
Gilead: 2-3
Eisai: 0
BI: 1?
AZ: 0?
seems not good at all!!!
ha
no |
|
n*****m
发帖数: 6 | 34 Fresh Organic Chemistry PhD, got an medicinal chemist position from Lilly (90K
). Is it possible to ask for higher? Say 95K-100K. Thanks.
Unfortunately the counter offer is even lower (89K, Eisai, process or
medicinal). Can anybody offer advice on the negotiation? Thanks again. |
|
|
|
|
|
|
c*********o
发帖数: 1734 | 40 准确的发音是：A仔。
我的前公司跟他们合作过。 |
|
|
|
|
|
|
s*******m
发帖数: 160 | 46 我也受到他家通知了，现在才面intern太晚了阿。 |
|
|
j*****7
发帖数: 4348 | 48 PhD + 8 yr exp上AD不是非常正常的吗？
在原单位拿不到的话，至少跳一槽就应该能搞定了。你去Forest Labs, Eisai看看，大
把PhD + 6 yr的AD。
当然也不是说AD就一定能上150k，base 135k的AD我也见过。 |
|
n**********8
发帖数: 340 | 49 【 以下文字转载自 Chinook 俱乐部 】
发信人: niuniuzhu168 (妞妞), 信区: Chinook
标 题: Four Drug Stocks Facing FDA Approval Decisions in July
发信站: BBS 未名空间站 (Wed Jul 4 00:08:43 2012, 美东)
BOSTON (TheStreet) -- Four FDA drug approval decisions in July -- headlined
by another weight-loss drug and a prescription fish oil pill with
blockbuster potential -- will keep biotech investors busy in what is
normally one of the sector's slower months.
Vivus(VVUS_) is expected to learn the fate of its weight-loss pill Qnexa on
Tu... 阅读全帖 |
|
r******2
发帖数: 754 | 50 我卖了300手的PUT。如果不批，我就握在兜里了。
你看看他们的问题。没有新意。也找不出问题。
并不是真的有问题，都是一些假想性的问题。如果真要都做临床，估计ARNA把公司所有
的股票卖给DE，EISAI，都做不完 |
|
